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Objectives: The purpose of this analysis was to assess 
the real-life direct costs of drug delivery for frequently
used chemotherapeutic regimens in patients with relapsed
low-grade non-Hodgkin’s lymphoma (NHL).
Methods: This was a retrospective analysis of direct 
costs of drug delivery (acquisition plus administration) 
of relapsed low-grade NHL in 424 patients in Canada,
Germany, and Italy. Results were expressed as an average
treatment cost per patient for six cycles of chemotherapy.
Exchange rates used were $1 (Canada) = € 0.672, 1 DM
(Germany) = € 0.511, and 1 Lit (Italy) = € 0.000517.
Results: Direct costs of drug delivery were greater for
inpatients receiving ﬂudarabine (Canada € 12,669; Italy
€ 13,027) than for CHOP (Canada € 7856; Germany €
7218; Italy € 4251) or COP/CVP (Canada € 7360;
Germany € 8449). Treatment administration setting was
a major cost driver with inpatient treatment up to 9-fold
more expensive than the same regimen given to outpa-
tients. Drug administration costs comprised the largest
proportion of the total for each regimen in the inpatient
setting (69–98%). Costs of drug delivery in the outpatient
setting were 10% to 65% of those in the inpatient setting.
Again, ﬂudarabine was more expensive (Italy € 8493;
Canada € 7269) than CHOP (Canada € 4403; Germany
€ 2150; Italy € 1264) and COP/CVP (Canada € 3009;
Germany € 867). Administration costs were 2.5- to 15-
fold higher for inpatients compared to outpatients.
Conclusions: Costs of drug administration are a major
driver for total direct treatment costs in the treatment of
relapsed low-grade NHL and are at least as important 
as drug acquisition costs. Drug administration practices,
in terms of inpatient or outpatient treatment, are a major
factor in determining overall direct costs. Therapeutic
strategies, which offer shortened treatment duration
and/or a simple mode of administration, are likely to be
economically attractive.
Keywords: CHOP, COP, cost analysis, CVP, drug deliv-
ery, ﬂudarabine, non-Hodgkin’s lymphoma.
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ABSTRACT
Introduction
Non-Hodgkin’s lymphomas (NHLs) are a hetero-
geneous group of malignancies arising from the
uncontrolled proliferation of lymphatic cells. Over
the past 30 years, the developed world has seen 
a substantial increase in the incidence of NHL [1].
Since the early 1970s, the incidence of NHL has
increased by approximately 3% to 4% per year
[2–4]. In Germany and Italy in 1997, approximately
14 per every 100,000 people of the population were
diagnosed with NHL [5]. Higher incidence rates
were reported in the United States, with around
53,000 new cases a year or approximately 20 cases
in every 100,000 people [6]. The reasons for this
increase are as yet unclear although a role for envi-
ronmental factors, including pesticides, solvents, or
dyes, has been postulated [3].
NHLs are most commonly of B-cell origin and
can be divided into two main groups according to
etiology and response to treatment: low-grade and
high-grade. Low-grade B-cell lymphomas are char-
acterized by low proliferate activity and a high pro-
portion of resting cells. Patients have a median
survival time of 3 to 8 years from the time of diag-
nosis during which time serial remissions often
occur, gradually decreasing in duration regardless of
treatment [6].
Initial management for asymptomatic patients 
is most commonly a period of “watch and wait”
with progression usually being observed within
18 months. After progression, a single alkylating
agent such as chlorambucil or an alkyl agent based
combination regimen is used in ﬁrst-line treatment.
Response rates as high as 80% have been observed
with a median duration of response of 12 to
30 months [7]. Upon subsequent relapse, patients
are offered further chemotherapy, typically under-
going several cycles of relapse and therapy.
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At present, there is no standard treatment for
relapsed low-grade NHL and a range of therapies
are available. Some of these are internationally rec-
ognized such as cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) and cyclophos-
phamide, vincristine, and prednisone (CVP/COP),
and others are more speciﬁc to a particular country,
such as dexamethasone, high-dose cytarabine, and
cisplatin (DHAP) in France. Recent studies have
shown promising results with ﬂudarabine, a purine
analog and rituximab, an anti-CD20 antibody with
better tolerability compared to chemotherapeutics
[8–16].
The range of available treatments for low-grade
NHL, many of which show comparable efﬁcacy,
mean that economic factors and patient quality of
life are particularly important considerations when
selecting the best treatment option. However, exten-
sive literature searches have revealed very few pub-
lished accounts of economic analyses of the direct
or indirect costs of NHL, despite the obvious need
for such information in many aspects of oncology
management [17,18]. An analysis of resource uti-
lization and treatment costs of different schedules
(CHOP vs. ﬂudarabine vs. rituximab) for relapsed
low-grade NHL in the United Kingdom was pub-
lished [19]. This study showed that overall treat-
ment costs (exchange rate 1 £ = € 1598) were higher
with ﬂudarabine (€ 15,895) than CHOP (€ 11,435)
or rituximab (€ 9642), which was associated with
signiﬁcantly fewer adverse events and therefore
lower total cost per patient.
The purpose of this analysis was to summarize
the direct costs of drug delivery for patients with
relapsed low-grade NHL in Canada, Germany, and
Italy. It provides the ﬁrst economic data on treat-
ment patterns and resource use for drug delivery 
in the treatment of relapsed low-grade NHL across
different countries and identiﬁes the main cost com-
ponents for each regimen.
Methods
Design
This was a retrospective analysis of the direct costs
of drug delivery of relapsed low-grade NHL in
patients. Information was collected from specialists
in all three countries by telephone interviews to
identify the most frequently used treatment regi-
mens. Case record forms (CRFs) were completed
retrospectively to collect clinical and resource uti-
lization data based on information from patient
records.
Data Collection
A total of 91 telephone interviews with oncologists,
hematologists, or lymphoma specialists were con-
ducted to determine the most commonly used treat-
ment regimens for relapsed low-grade NHL in
Canada (31 specialists), Germany (30 specialists),
and Italy (30 specialists). An independent market
research company (ISIS Research, UK) performed
interviews by using native language speakers and a
set questionnaire. At the start of each interview,
determining that the interviewees either specialized
in lymphoma management or ran a hospital lym-
phoma clinic and treated 10 or more patients with
relapsed low-grade NHL per year assessed eligibil-
ity. Eligible specialists were then asked which treat-
ment regimens were most commonly used to treat
the condition and the number of patients receiving
each regimen.
In a second step, CRFs designed to obtain retro-
spective data from patient records were sent to 179
eligible specialists. Each CRF recorded information
on resource utilization for drug delivery, that is,
inpatient visits, outpatient visits, and routine diag-
nostic tests from a single cycle of chemotherapy
(typically, the studied regimens comprised six cycles
of chemotherapy). Patients who stayed in the hos-
pital for at least one night for drug administration
were considered to be inpatients and all others were
deﬁned as outpatients. Data were collected from
patients with relapsed low-grade NHL treated 
after 1990 and receiving treatment with one of 
the selected regimens chosen on the basis of most
common usage in each country. No further criteria
for patient sampling were employed. Mailing and
collection of CRFs was performed by an indepen-
dent market research organization to maintain 
conﬁdentiality. Recruitment of 50 patients per treat-
ment group and country was targeted.
Eighty-nine of 179 specialists (Canada 50,
Germany 20, and Italy 19) returned completed ret-
rospective CRFs providing data on 424 patients in
total (Canada 173, Germany 99, and Italy 152). In
Canada, the number of available patients was com-
parable for all three treatment regimens (CHOP 57,
COP/CVP 56, and ﬂudarabine 60) (Table 1). Data
from a similar number of patients for CHOP and
COP/CVP were available from Germany (CHOP 
48 and COP/CVP 51) and, from Italy, data were
provided for 70 patients on CHOP and 82 on 
ﬂudarabine.
Cost Calculations
Costs for each selected regimen were calculated
from the perspective of a third-party payer based on
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1997 costs. The cost per patient of a single cycle of
chemotherapy was calculated for each country. Unit
costs were estimated from several different sources
in each country including previously published eco-
nomic studies, published price lists and national and
regional information sources [20–30]. For Italy, the
mandatory 50% reduction for drugs in hospitals
was considered. Each cycle was assumed to be 
representative of the whole course of treatment 
for each patient and results were expressed as an
average direct cost of drug delivery per patient for
a complete course of chemotherapy (six cycles).
Average costs per patient were calculated in both
the inpatient and outpatient settings.
Direct costs of drug delivery were calculated as
the sum of the drug administration costs and the
cost of drugs used in the regimen (drug acquisition).
Drug administration costs included both outpatient
visits and hospitalizations for administration of the




Fifteen different therapies were identiﬁed as being
used to treat relapsed low-grade NHL in Canada,
Germany, and Italy. Specialists in Canada most
commonly cited COP/CVP followed by CHOP (20
of 31) and ﬂudarabine (18 of 31). In Germany,
CHOP and COP/CVP were used most often (both
14 of 30 specialists). The most commonly used
treatment regimens by specialists in Italy were
CHOP (14 of 30) and ﬂudarabine (13 of 30).
Based largely on the highest levels of usage in
each country, CHOP, ﬂudarabine, and COP/CVP
were selected for economic analysis in Canada,
CHOP and COP/CVP in Germany, and CHOP and
ﬂudarabine in Italy.
Patient Characteristics
The sex and average age of patients in the study was
comparable across treatment regimens and coun-
tries (Table 1). The average number of previous
treatments was also comparable between the treat-
ment regimens and countries. Overall, there were
very few notable differences between treatment 
regimens and stage of disease. However, patients
treated with ﬂudarabine in Canada or COP/CVP in
Germany were less likely to be in Stage IV of their
disease than patients in their respective countries
treated with other regimens.
Most of the patient treatment cycles reported by
the specialists occurred both early (ﬁrst or second)
and late (ﬁfth or sixth+) in a treatment course, such
that the data collected may be considered to be 
a reasonable representation of the “average” cycle.
The estimated direct costs of drug delivery were
therefore assumed to represent those of an average
treatment cycle.
Direct Costs of Drug Delivery of Different Regimens
Unit costs were comparable between countries with
the exception of costs for outpatient visits, which
were highest in Canada (Table 2). They were used
to calculate total direct costs of drug delivery for
relapsed low-grade NHL in inpatients and outpa-
tients in Canada, Germany, and Italy (Fig. 1). In 
the inpatient setting, overall costs of CHOP and
COP/CVP treatment regimens were comparable
within Canada and Germany. Due to the higher
number of administrations per cycle, ﬂudarabine
treatment was substantially more expensive than
CHOP treatment. In the outpatient setting, costs of
drug delivery were 10% to 65% of those in the
inpatient setting. Due to high drug acquisition costs
and a higher number of administration visits per
cycle, ﬂudarabine was more expensive than CHOP
and COP/CVP.
Table 1 Patient characteristics
Canada Germany Italy
CHOP COP/CVP FLU CHOP COP/CVP CHOP FLU 
(n = 57) (n = 56) (n = 60) (n = 48) (n = 51) (n = 70) (n = 82)
Average age (years) 58 58 62 58 63 62 64
No. of males vs. females 35 vs. 22 24 vs. 32 35 vs. 25 26 vs. 22 34 vs. 17 43 vs. 27 55 vs. 27
Average no. of previous treatments 1.6 1.4 1.5 1.4 1.5 1.5 1.7
Stage of disease (%)
I 5 3 5 6 2 3 0
II 12 10 20 17 12 14 7
III 23 13 29 19 53 31 38
IV 60 73 46 58 33 51 55
Abbreviation: FLU, ﬂudarabine.
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Cost Differences between Countries
When total costs of drug delivery for each regimen
were compared between countries, no one country
demonstrated consistently higher costs for disease
treatment.
CHOP therapy was most costly in Canada and
least expensive in Italy regardless of inpatient or
outpatient administration. Indeed, the greatest dif-
ference in costs between countries occurred with
CHOP.
For both COP/CVP and ﬂudarabine therapy, the
differences were less marked. COP/CVP treatment
was slightly more expensive in Germany than in
Canada for inpatient administration, but the situa-
tion was reversed and signiﬁcantly different for 
outpatients. The costs of ﬂudarabine treatment in
Canada and Italy were comparable for inpatient
and outpatient administration.
Cost Drivers
When therapy was given in the inpatient setting,
administration costs formed the major cost compo-
nent for each regimen studied (Table 3). The cost of
administration represented 72% to 89% of the total
costs of drug delivery for CHOP, 96% to 98% for
COP/CVP treatment, and approximately 70% of
those for ﬂudarabine. In contrast, the proportion 
of drug delivery cost for outpatients taken up by
administration appeared to be inﬂuenced more by
country than regimen. In Canada, the administra-
tion costs for outpatients was consistently the
highest (factor of 4–7) predominantly due to the
high unit costs per outpatient visit.
Fludarabine treatment was the most expensive
across the three treatment regimens (Table 3). Drug
acquisition costs contributed 54% to 91% to the
cost of ﬂudarabine treatment in the outpatient
setting and contributed approximately 30% of the
total cost for inpatient administration. In contrast,
drug acquisition represented only 2% to 28% of 
the total for CHOP and COP/CVP therapy for 
inpatients.
As expected, total costs for the treatment of inpa-
tients were greater in all situations than for outpa-
tients due to the increased costs of administration.
The difference in cost of administration between
inpatient and outpatient treatment settings was 10-
to 15-fold in Italy and Germany and approximately
slightly higher than 2-fold in Canada.
Sensitivity Analysis
A multivariate sensitivity analysis including all 
relevant variables was conducted to test the robust-
ness of results and conclusions. The numbers of
visits (either inpatient or outpatient) and drug
acquisition costs were considered to be relatively
stable because of deﬁned numbers of administra-
tions in the respective treatment regimes or price
lists. These two items were varied between 75 and
125% of the observed values. All other parameters
(number and costs of diagnostic tests, costs for out-
patient and inpatient visits) were varied between 50
and 200%.
Although absolute costs increased or decreased
according to changed assumptions, no major
changes in relative costs leading to different 
conclusions occurred between regimens, treatment 
settings, or countries when all parameters were 
set to either minimum or maximum levels (Figs. 2
and 3).
To induce relevant changes the following manip-
ulations were necessary: 1) outpatient treatment for
Table 2 Summary of unit costs by country
Canada Germany Italy
Cost (€)* Ref. Cost (€)* Ref. Cost (€)* Ref.
Inpatient stay 350.11 [20] 332.15 [24] 359.26 [30]
Outpatient visit 127.01 [21] 16.25 [24] 25.85 [27]
Selected diagnostic tests
Complete blood count 14.58 [20] 5.52 [24] 3.21 [28]
U & E 8.55 [22] 3.68 [24] 1.24 [28]
Platelets 8.55 [22] 1.84 [24] 1.24 [28]
Blood culture 12.79 [22] 9.20 [24] 2.07 [28]









































Figure 1 Total costs of drug delivery.
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all regimen became more expensive than inpatient
treatment in Canada when costs for outpatient
visits were increased to >139% and costs for
overnight stays were lowered to 50% compared 
to baseline; and 2) inpatient treatments with
COP/CVP and CHOP in Canada were similar.
Therefore, relatively small changes in drug costs or
number and costs of visits let one or the other
regimen become the cheaper one (reducing drug
costs or increasing costs of visits favors CHOP).
No combination of variations of parameters
changed the conclusions for Italy and Germany.
Excluding costs for drugs and tests for inpatient
treatment in Germany (to better reﬂect the 
third-party payer perspective) had only a minor
impact on the ﬁgures and did not notably affect the
results.
Discussion
This is the ﬁrst international analysis of direct costs
of drug delivery associated with conventional
chemotherapeutic treatment of relapsed low-grade
NHL. The results indicate that, irrespective of the
country or the regimen used, drug acquisition costs
made up less than half of the overall direct costs of
drug delivery in the inpatient setting. Administra-
tion setting had a major inﬂuence on the total cost
of treatment. Inpatient administration increased the
cost of drug delivery up to ninefold over the same
treatment in an outpatient setting. Administration
costs comprised the largest proportion of the total
for each regimen in the inpatient setting (69–98%).
This suggests that potential savings due to a reduc-
tion of overnight stays in hospital for administra-
tion of chemotherapy would be substantial.
Comparison of direct costs of drug delivery
between countries revealed no obvious trends, with
the exception of outpatient administration costs.
These were much higher in Canada than in the
other two countries. This reﬂects the higher unit
costs of an outpatient visit in Canada (€ 127) than
in Germany (€ 16) or Italy (€ 26). In contrast, the
costs for an inpatient stay in a nonintensive care
unit were similar in all three countries (Canada 
€ 350; Germany € 332; Italy € 359). In Germany, 
a proportion of patients received COP/CVP as a 
“5-day-COP/CVP” regimen which required ﬁve
(instead of one) drug administrations per cycle-
regimen. This caused the relatively high costs.
Table 3 Breakdown of the average cost per patient into administration (Admin) and drug acquisition (Acq) costs for inpa-
tients and outpatients
Inpatient (€)* Outpatient (€)*
Regimen/country Admin Acq Total Admin Acq Total
CHOP
Canada 5639 2217 7,856 2187 2216 4403
Germany 5512 1706 7,218 444 1706 2150
Italy 3781 470 4,251 335 929 1264
COP/CVP
Canada 7198 162 7,360 2847 162 3009
Germany 8088 361 8,449 506 361 867
Fludarabine
Canada 8738 3931 12,669 3338 3931 7269
Italy 9166 3861 13,027 770 7723 8493
*Exchange rates: $1 (Canada) = € 0.672; 1 DM (Germany) = € 0.511; 1 Lit (Italy) = € 0.000517.
0 5,000 10,000
Sensitivity Analysis Costs for In-Patients (C)














Figure 2 Sensitivity analysis of inpatient costs.













–Sensitivity Analysis Costs for Out-Patients (C)
Figure 3 Sensitivity analysis of outpatient costs.
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Financial considerations could also affect the
management of patients. For example, in some hos-
pitals in Germany reimbursement depends on the
patient having an overnight stay; therefore, inpa-
tient administration may be inﬂuenced by ﬁnancial
rather than medical reasons. This could account for
the relatively high proportion of patients (46–51%)
in Germany who received treatment as inpatients
(Table 4).
Only one other analysis of the costs of treating
relapsed low-grade NHL has been reported to date.
This was a retrospective analysis of patient records
conducted in the UK and assessed costs for patients
treated with CHOP, ﬂudarabine, or rituximab at
several treatment centers in a Phase II clinical trial.
Interestingly, the overall direct costs of drug deliv-
ery for CHOP, COP/CVP, and ﬂudarabine therapy
were comparable in the UK study, with those
reported with those reported in this study for
Canada, Germany, and Italy. In addition, although
the comparison of chemotherapy and rituximab
from different data sources should be treated with
caution, the UK study showed total direct treatment
costs were comparable for rituximab and CHOP
but less than ﬂudarabine. Lower costs for drug
administration in combination with the superior
tolerability of rituximab offset the higher drug
acquisition costs of rituximab.
The telephone survey employed in the ﬁrst stage
of the present study demonstrated the lack of a stan-
dardized treatment approach to relapse low-grade
NHL within and between the countries studied.
This observation is supported by data from the UK
published by Sweetenham et al. [19]. The number
and variety of regimens employed may well reﬂect
similarities in response rates and remission times
among the available therapies and emphasizes the
need for new treatment strategies [31]. Indeed, the
similarity of response with the regimens investi-
gated here has been well documented [19,32–35]
and, in the absence of new treatment strategies, par-
ticular emphasis will be placed on tolerability and
cost-effectiveness by clinicians when deciding which
treatment regimens to use. Therefore, economic
studies such as this one may well provide valuable
information for the future management of patients
with low-grade NHL.
A possible criticism of studies, which use retro-
spective collection of data using patient records as
opposed to data from randomized trials, is that pre-
selection bias could be a factor, introduced by the
selection of patients for a particular protocol (based
on age, stage, response to previous regimen, etc.).
However, it could be argued that data collected in
retrospective analyses better reﬂect the real-life sit-
uation as a cross-section of patients are assessed as
opposed to sequentially enrolled subjects. Indeed, in
economic studies such as this, “patient selection”
and a closer reﬂection of the real-life situation may
well be more suitable. The use of data from patient
records further underlines that the study data
reﬂects the real-life situation.
Some bias in cycle or patient selection may have
occurred because the selection of consecutive cases
was not speciﬁed, nor was the selection of early or
late cycles predeﬁned. However, the distribution of
patient cycles from the 424 records returned sug-
gests that this was not a major factor, because there
was a even distribution of patients undergoing early
cycles (cycles 1–3, 48%) and late cycles (cycles 4+,
50%). Similarly, patient characteristics (Table 1) 
do not show any major imbalances between the
groups, and no evidence for patient selection was
found.
Patient selection would have been more of a
potential issue if outcomes, such as efﬁcacy para-
meter, had been collected. For the assessment of
resource utilization for drug delivery potential
patient selection is expected to have limited impact
only as drug delivery for the regimens were deﬁned
by treatment schedules.
It is generally accepted that studies that draw com-
parisons between countries should be interpreted
with a degree of caution, particularly with respect to
factors that are potentially country-speciﬁc, such as
patient selection criteria or regulations. However, the
preparation of a single retrospective CRF for use in
all three countries investigated here should, at least
in part, address this concern.
Conclusion
This study shows that drug administration costs are
a major driver for total direct costs of drug deliv-
ery in the treatment of relapsed low-grade NHL and
are at least as important as drug acquisition costs.
Drug administration practices, in terms of treat-
ment inpatient or outpatient treatment, are a major
factor in determining overall direct costs. Thera-
Table 4 Number (%) of patients receiving at least one infu-
sion of the treatment regimen in the inpatient setting
(overnight stay in hospital)
CHOP COP/CVP Fludarabine
Canada 7/57 (12) 8/56 (14) 4/60 (7)
Germany 22/48 (46) 26/51 (51) —
Italy 13/70 (19) — 31/82 (38)
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peutic strategies, which offer shortened treatment
duration and/or a simple mode of administration,
are likely to be economically attractive.
This study was funded by Hoffmann-La Roche, Basel,
Switzerland.
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